NCT02205515View on ClinicalTrials.gov

An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2021

Study Completion Date

October 31, 2021

Conditions

Carcinoma, Neuroendocrine

Interventions

DRUG

Everolimus

Everolimus is a novel derivative of rapamycin.

Trial Locations (1)

M4N 3M5

Odette Cancer Centre, Sunnybrook Health Science Centre, Toronto

All Listed Sponsors

lead

Sunnybrook Health Sciences Centre

OTHER

NCT02205515 - An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis | Biotech Hunter | Biotech Hunter